maia: 5-year follow-up on drd vs rd in newly diagnosed myeloma
Published 3 years ago • 339 plays • Length 2:16Download video MP4
Download video MP3
Similar videos
-
1:08
long term follow-up results from the phase iii maia trial in myeloma
-
1:53
updated analysis of maia: d-rd continues to beat rd in transplant-ineligible ndmm
-
4:03
maia and alcyone: follow-up of daratumumab in multiple myeloma
-
2:37
updated analysis of the maia trial: long-term safety and efficacy data
-
2:41
maia: dara-len-dex demonstrates prolonged pfs in multiple myeloma
-
1:31
five-year follow-up of olutasidenib for idh1-mutated r/r aml
-
3:08
frailty subgroup analysis of the maia trial
-
1:39
the next five years of multiple myeloma treatment
-
6:23
how long will i live with multiple myeloma and is there a cure?
-
10:11
daratumumab interference in pre-transfusion testing
-
8:07
lenalidomide in del 5q mds
-
2:53
a 5-year follow-up of ruxolitinib plus azacitidine in mds/mpn overlap syndromes and cmml
-
2:06
long-term follow-up from the uk myeloma xi trial
-
2:21
the treatment of young and fit, older and fit, and frail patients with multiple myeloma in ireland
-
6:20
5-year data supports efficacy and safety of daratumumab as add-on therapy for multiple myeloma
-
1:53
the future of multiple myeloma treatment
-
2:17
moving towards fixed-duration treatment in multiple myeloma
-
5:07
daratumumab in the management of al amyloidosis
-
0:51
challenges in managing myeloma patients
-
1:13
updated maia trial data show improved survival for multiple myeloma
-
0:40
approval of dvd for myeloma at first relapse in the uk: impacts on care
-
2:20
ultra high-risk myeloma